I-125 seeds with chemotherapy for progressive non-small-cell lung cancer after first-line treatment: a meta-analysis

Table 2 Characteristics of the treatments

Study	First-line chemotherapy	Second-line chemotherapy	Groups	CR	PR	SD	PD
Luo [11]	Paclitaxel, Cisplatin*	Docetaxel, Cisplatin	Chemotherapy alone	1	6	6	4
Luo [11]	Paclitaxel, Cisplatin*	Docetaxel, Cisplatin	Combined	7	4	4	2
Xiang [12]	Paclitaxel, Cisplatin, Gemcitabine, Carboplatin*	Docetaxel, Pemetrexed	Chemotherapy alone	1	16	17	7
Xiang [12]	Paclitaxel, Cisplatin, Gemcitabine, Carboplatin*	Docetaxel, Pemetrexed	Combined	13	14	15	2
Xiang [13]	Not given*	Docetaxel, Pemetrexed	Chemotherapy alone	9	31	38	16
Xiang [13]	Not given*	Docetaxel, Pemetrexed	Combined	21	47	41	7
Yu [14]	Paclitaxel, Cisplatin*	Docetaxel, Pemetrexed	Chemotherapy alone	2	13	8	3
Yu [14]	Paclitaxel, Cisplatin*	Docetaxel, Pemetrexed	Combined	10	8	6	2
Zhang [15]	Paclitaxel, Cisplatin, Gemcitabine	Docetaxel, Pemetrexed	Chemotherapy alone	7	17	25	15
Zhang [15]	Paclitaxel, Cisplatin, Gemcitabine	Docetaxel, Pemetrexed	Combined	24	33	10	0
Zheng [16]	Paclitaxel, Cisplatin, Gemcitabine	Docetaxel, Cisplatin	Chemotherapy alone	0	6	29	9
Zheng [16]	Paclitaxel, Cisplatin, Gemcitabine	Docetaxel, Cisplatin	Combined	2	22	16	2

CR complete response, PR partial response, SD stable disease, PD progression disease
*These studies used concurrent chemoradiotherapy as the first-line treatment

ISSN: 1749-8090